China Pharmaceutical Regulatory Updates | July 2022

Aug. 10th, 2022
4137

This is a collection of China’s recent pharmaceutical laws, regulations, policies, and standards, mainly issued by the following authorities:

  • National Medical Products Administration (NMPA);
  • NMPA’s Center for Drug Evaluation (CDE);
  • National Health Commission (NHC);
  • National Healthcare Security Administration (NHSA);
  • National Joint Drug Procurement Office;
  • Chinese Pharmacopoeia (ChP) Commission.

pharmaceutical regulation china

China‘s 7th Volume-based Procurement Includes 327 Drug Products


On July 18, China National Joint Drug Procurement Office announced the official list of 327 drug products for the 7th volume-based procurement (VBP). 217 bid-winning companies will supply the products to public health institutions. Among the companies, 6 are international enterprises—Hetero Labs, Bracco Sine, Almirall, Sandoz, and Pfizer. Please refer to China Announces Final Result of the 7th Volume-based Procurement (VBP) for Drugs for more details.

China NMPA Grants One Rx-to-OTC Switch


On July 11, China NMPA granted the OTC status to a former prescription drug Glucosamine Potassium Sulfate Tablets. View China’s OTC medicine list at BaiPharm Database. Find out how to sell OTC drugs to China via cross-border e-commerce at BaiPharm Insight/Webinar.

Webinar: How to Sell OTC Drugs to China via Cross-border E-commerce

China NMPA Issues the 56th List of RLDs


On July 22, China NMPA released the 56th list of reference listed drugs (RLDs), including Teva Pharmaceuticals’ Floxapen, Novartis Japan K.K.’s Betoptic and other 72 drugs. RLDs are reference products to which that generic drugs shall be equivalent in quality and efficacy. View the RLD lists at BaiPharm Database.

China NMPA Implements Vaccine Manufacture & Distribution Rules


On July 8, China NMPA started implementing the Administrative Rules on Vaccine Manufacture and Distribution (hereafter referred to as the Rules).  According to the Rules, China adopts the marketing authorization holder (MAH) system for vaccines. MAHs shall take the primary responsibilities for vaccine’s safety, efficacy, and quality controllability, and manage the manufacture and distribution of vaccines. Check out more details at Breaking: Immediate Effect of China’s Vaccine Manufacture & Distribution Rules.

China CDE Consults on Procedures for Starting For-Cause Inspections


On July 7, CDE released the draft of Work Procedures for Initiating For-cause Inspections During Drug Review for public comments. For-cause inspections will be initiated by CDE if the drug application data are found to be suspiciously inauthentic or the drugs are reported to have problems during the review, and the issues need to be verified on site. When necessary, CDE can conduct sample tests.

Related Article: China to Initiate Pre-Approval Inspections Based on Risk Levels of Drug Registration Applications

China CDE Releases Q&As on Immediate Report of Adverse Drug Reactions (ADRs) in Clinical Trials


On July 19, CDE consulted on the Q&As on the Immediate Report of Safety Data During Drug Clinical Trials (Version 2.0). CDE clarifies the scopes of drugs and clinical trials for which applicants should immediately report the unexpected and severe ADRs that are confirmed/suspected to be relevant to the test drugs.

The involved drugs cover traditional Chinese medicines, chemical drugs, and biological products, including vaccines.

The clinical trials include:

  • Phase I/II/III clinical trials related to drug registration;
  • Bioequivalence studies approved according to investigational new drug (IND) applications;
  • Phase IV clinical trials particularly required in the drug approval document;
  • Clinical trials required for drugs with conditional approval.
  • Clinical trials required for marketed drugs that apply for adding a new target group or a new indication.
  • Clinical trials required for marketed drugs that have major variations (e.g. new dosage form, new administration route, new manufacturing technique, etc.)

Time limits for the immediate reports:

Ÿ   For unexpected and severe ADRs that are deadly or life-threatening, the applicant should report them as soon as possible—no later than the 7th day from the first knowledge* of the ADRs. The applicant should complete the follow-up information in the subsequent 8 days after the report date.

Ÿ   For unexpected and severe ADRs that are neither deadly nor life-threatening, the applicant should report them as soon as possible—no later than the 15th day from the first knowledge of the ADRs.

*The first knowledge means that the applicant has known about the ADRs for the first time. The day when the applicant gets the first knowledge is defined as the zeroth day.

Related Article: China Releases MedDRA Coding Guidance for Adverse Drug Reaction (ADR) Reports

Pharmaceutical Guidelines/Standards


No. Guidelines/Standards Authority Status Release Date
1 Guidelines on General Considerations for Organizing Patients to Joining in Drug Development CDE Draft July 6
2 Technical Guidelines on Antibody-drug Conjugates (ADCs)’ Non-clinical Researches CDE Draft July 6
3 Technical Guidelines on Alcohol-induced Dose-dumpling Tests for Oral Modified-release Formations of Generic Drugs CDE Draft July 7
4 Guidelines on the Design and Plan Framework of Real World Studies on Drugs CDE Draft July 7
5 Technical Guidelines on Bioequivalence Studies on Amphotericin B Liposome for Injection CDE Draft July 7
6 Guidelines on Clinical R&D of New Drugs for Acute Myeloid Leukemia (AML) CDE Draft July 19
7 Technical Guidelines on Drug Registration Based on Animal Rules CDE Draft July 22
8 Guidelines on Blinded Clinical Trials of Drugs CDE Draft July 25
9 ICH M12 Guideline on Drug Interaction Studies CDE Draft July 29
10 Monograph: Lincomycin Hydrochloride Injection Chinese   Pharmacopoeia (ChP) Commission Revised   Draft July 7
11 Monograph: Clindamycin Phosphate Injection ChP Commission Revised Draft July 7
12 Monograph: Calcium Carbonate ChP Commission Draft July 7
13 Monograph: Nitrogen ChP Commission Draft July 7
14 Guidelines on Determining the Flowability of Powder ChP Commission Draft July 7
15 9650 Research Guidelines on Sealing Properties of Pharmaceutical Packaging Systems ChP Commission Draft July 11
16 *No. 16-40 are draft standards of pharmaceutical packaging materials

5510 General Chapter on Prefilled Syringes

ChP Commission Draft July 11
17 5511 General Chapter on Glass Barrels of Prefilled Syringes ChP Commission Draft July 11
18 5512 General Chapter on Plastic Barrels of Prefilled Syringes ChP Commission Draft July 11
19 5513 General Chapter on Stainless Steel Needles of Prefilled Syringes ChP Commission Draft July 11
20 4040 Test for Luer Taper of Prefilled Syringes ChP Commission Draft July 11
21 4041 Sealing Property Test for Protective Caps of Prefilled Syringes ChP Commission Draft July 11
22 4042 Pull-off Force Test for Protective Caps of Prefilled Syringes ChP Commission Draft July 11
23 4043 Sealing Property Test for Pistons of Prefilled Syringes ChP Commission Draft July 11
24 4044 Unscrewing Torque Determination for Luer Lock Rigid Tip Caps of Prefilled Syringes ChP Commission Draft July 11
25 4045 Torsion Resistance Determination for Adapter Collars of Prefilled Syringes ChP Commission Draft July 11
26 4046 Pull-off Force Determination for Adapter Collars of Pre-filled Syringes ChP Commission Draft July 11
27 4209 General Chapter on the Determination of Ethylene Oxide in Pharmaceutical Packaging Materials ChP Commission Draft July 11
28 4226 Determination of Tungsten Dissolution Amount in Prefilled Syringes ChP Commission Draft July 11
29 4227 Determination of Silicone Oil in Prefilled Syringes ChP Commission Draft July 11
30 5200 General Chapter on Rubber Closures for Pharmaceutical Packaging ChP Commission Draft July 13
31 5201 General Chapter on Rubber Closures for Injections’ Packaging ChP Commission Draft July 13
32 5202 General Chapter on Rubber Closures for Oral Dosage Forms’ Packaging ChP Commission Draft July 13
33 4204 Determination of Extractables and Leachables of Pharmaceutical Packaging Materials ChP Commission Draft July 14
34 4206 Determination of Insoluble Particles in Pharmaceutical Packaging Materials ChP Commission Draft July 15
35 4214 Determination of Metal Elements and Ions in Pharmaceutical Packaging Materials ChP Commission Draft July 16
36 4219 Determination of Volatile Sulfide in Rubber Closures ChP Commission Draft July 17
37 4220 Determination of Ash Content in Rubber Closures ChP Commission Draft July 18
38 4221 Determination of Water Content in Rubber Closures ChP Commission Draft July 19
39 4222 Determination of Silicone Oil on the Surface of Rubber Closures ChP Commission Draft July 20
40 4223 Determination of Special Residues in Silicone Rubber Closures ChP Commission Draft July 21
41 Monograph: Minocycline Hydrochloride Tablets ChP Commission Revised Draft July 20
42 Monograph: Bismuth Subnitrate ChP Commission Draft July 20
43 Monograph: Bismuth Subnitrate Tablets ChP Commission Draft July 20
44 Monograph: Magnesium Sulfate Injection ChP Commission Revised   Draft July 20

Reprinted from: ChemLinked

For more details about the summarized contents below, please send an enquiry to contact@chemlinked.com.

Reference Links


Contact Us


BaiPharm, a subsidiary of REACH24H Consulting Group, is specialized in pharmaceutical industry consultancy services. With our experts across China, Japan, South Korea, the United States, and Europe, BaiPharm is fully qualified to engage in complex market entry projects of finished drugs, APIs, excipients, and packaging materials for most key markets.

If you have any questions about pharmaceutical regulatory compliance in China, please feel free to contact us.

Tel: +86 (0)571-87007555

Email: customer@reach24h.com